Research & Education

Breakthrough Drug Approval Signals Great Advances in Lung Cancer Treatment

DENVER, Colo. – The International Association for the Study of Lung Cancer (IASLC) says the move by the U.S. Food and Drug Administration (FDA) to grant accelerated approval for a cutting-edge lung cancer treatment is a positive step forward that may help many patients improve their survival.

Abstracts Featured in WCLC 2015 Press Program

DENVER, Colo. – The International Association for the Study of Lung Cancer (IASLC) featured several scientific abstracts during the 16th World Conference on Lung Cancer (WCLC) press program. Below are links to the releases for each individual abstract.

Advanced Treatment and Prognosis Data Available for Tumor, Node and Metastasis (TNM) Classification of Lung Cancer

DENVER, Colo. – The publication of the Eighth Edition of the Tumor, Node and Metastasis (TNM) Classification of Lung Cancer will provide physicians around the world access to new data to more precisely stage and treat cases of lung cancer. That data, collected by the International Association for the Study of Lung Cancer (IASLC) Staging and Prognostic Factors Committee and presented at the 16th World Conference on Lung Cancer (WCLC) in Denver on Tuesday, Sept. 8, 2015 at the Colorado Convention Center, will be published in 2016.

Adding Bevacizumab to Standard Treatment Improves Overall Survival in Patients with Malignant Pleural Mesothelioma

DENVER, Colo. — Adding the angiogenesis inhibitor bevacizumab to standard treatment for malignant pleural mesothelioma (MPM) increases life expectancy without severe toxicity, according to research presented today at 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC). The French multicenter randomized phase 3 trial data was presented by Dr. Arnaud Scherpereel, Head of the Pulmonary and Thoracic Oncology Department and Professor at the University Hospital (CHU) of Lille, France.

Results From Phase III Trials of Anamorelin in Advanced Non-Small Cell Lung Cancer Patients with Cachexia: ROMANA 1 and 2

DENVER, Colo. — Two Phase III studies with anamorelin found that the medication effectively combats wasting and increases body weight and lean body mass in certain lung cancer patients. Results from the ROMANA 1 and ROMANA 2 Phase III trial of anamorelin were presented today in Denver, Colo. at the 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC).

Impact of Time to Drug Approval on Potential Years of Life Lost: The Compelling Need for Improved Trial and Regulatory Efficiency

DENVER, Colo. — Every hour lost to the cancer drug regulatory process costs 29 life-years lost in the U.S. and 260 life-years worldwide, according to research presented today at 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC). Dr. David Stewart, Head, Division of Medical Oncology, University of Ottawa/The Ottawa Hospital, presented data on how the regulatory process of new therapies slows progress by increasing drug developments costs and by producing speed bumps that delay approval of useful drugs. This process also increases resources required to document that other agents are ineffective.

Pages